Ribon Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT04053673
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ribon Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

rbn-2397 (2 trials)

Drugs in Phase 1 Trials (1)

rbn-3143 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2